Jaffetilchin Investment Partners LLC bought a new position in Athenex Inc (NASDAQ:ATNX) in the 4th quarter, HoldingsChannel.com reports. The fund bought 107,608 shares of the company’s stock, valued at approximately $1,711,000.
Several other institutional investors have also modified their holdings of ATNX. Bank of New York Mellon Corp purchased a new stake in shares of Athenex during the second quarter worth $240,000. Laurion Capital Management LP purchased a new stake in shares of Athenex during the second quarter worth $1,600,000. Vanguard Group Inc. purchased a new stake in shares of Athenex during the second quarter worth $800,000. California Public Employees Retirement System purchased a new stake in shares of Athenex during the second quarter worth $800,000. Finally, OxFORD Asset Management LLP purchased a new stake in shares of Athenex during the second quarter worth $956,000. 2.93% of the stock is owned by institutional investors and hedge funds.
Athenex Inc (NASDAQ ATNX) traded down $0.14 during midday trading on Wednesday, reaching $15.41. The company’s stock had a trading volume of 319,800 shares, compared to its average volume of 168,783. Athenex Inc has a one year low of $11.21 and a one year high of $20.79. The company has a market capitalization of $897.77 and a price-to-earnings ratio of -5.58.
COPYRIGHT VIOLATION NOTICE: This report was published by Community Financial News and is the sole property of of Community Financial News. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright legislation. The legal version of this report can be read at https://www.com-unik.info/2018/01/10/jaffetilchin-investment-partners-llc-takes-1-71-million-position-in-athenex-inc-atnx.html.
Athenex Company Profile
Athenex, Inc is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company’s technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics.
Want to see what other hedge funds are holding ATNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Athenex Inc (NASDAQ:ATNX).
Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.